NCT06172283 is a NA clinical trial of Intermittent Fasting in Prostate Cancer, sponsored by State University of New York at Buffalo.

Who is sponsoring NCT06172283?

NCT06172283 is sponsored by State University of New York at Buffalo.

What drugs are being tested in NCT06172283?

Interventions in NCT06172283: Intermittent Fasting.

What condition does NCT06172283 study?

NCT06172283 studies Prostate Cancer.

Is NCT06172283 still recruiting?

NCT06172283 is currently recruiting now. Last updated 17 February 2025.

Last reviewed 2025-02-17 · How we verify

NCT06172283

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Recruiting now NA Last updated 17 February 2025

What this trial tests

NA trial testing Intermittent Fasting in Prostate Cancer in 30 participants. Currently enrolling.

Timeline

5 December 2023

Primary endpoint
1 January 2027

31 December 2028

Quick facts

Lead sponsor	State University of New York at Buffalo
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	5 December 2023
Primary completion	1 January 2027
Estimated completion	31 December 2028
Sites	1 location across United States

Drugs / interventions tested

Intermittent Fasting

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

State University of New York at Buffalo

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy. Study feasibility measures will include enrollment rate, drop-out rate and compliance with diet measured by self-reports.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Caloric Restriction Enhances the Efficacy of Antiandrogen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation.
Cordova RA, Elbanna M, Rupert C, Orsi SA, et al · · 2025 · cited 2× · PMID 40779415 · DOI 10.1158/0008-5472.can-24-1986
Intermittent Fasting and Androgen Receptor Signaling in Prostate Cancer: Metabolic Crosstalk and Therapeutic Implications.
Gromadzka G, Bendykowska M. · · 2026 · PMID 41898513 · DOI 10.3390/ijms27062652

Verify or expand the search:

Other trials of Intermittent Fasting

Trials testing the same drug.

NCT06615817 — Intermittent Fasting, Mediterranean Diet and NAFLD · NA · not yet recruiting
NCT06106477 — Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for · NA · recruiting
NCT06386887 — Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer · NA · recruiting
NCT06766747 — Efficacy of Intermittent Fasting Versus Continuous Caloric Restriction in the Treatment of Significant Weight Regain Aft · NA · completed
NCT05869747 — Firefighter Collaborative Research Project · NA · active not recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other State University of New York at Buffalo trials

Trials by the same sponsor.

NCT07072767 — Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation · NA · not yet recruiting
NCT07140848 — CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes · NA · not yet recruiting
NCT07433959 — Neuromodulation to Improve Grasping Function After SCI · NA · not yet recruiting
NCT07403539 — Speech Learning and Speech Production in Parkinson's Disease · NA · recruiting
NCT05367362 — Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06172283 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by State University of New York at Buffalo
Last refreshed: 17 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06172283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing